Cell and gene manufacturers benefit from surge in FDA drug approvals: GlobalData
Express Pharma
MAY 8, 2024
According to the statement released by GlobalData, 2023 marked a significant upsurge in FDA approvals, particularly for groundbreaking treatments such as cell and gene therapies. Even larger pharma companies will find difficulty in developing and producing cell and gene therapies solely in-house.
Let's personalize your content